A citation-based method for searching scientific literature

Joseph Chen, Ana Ruiz-Garcia, Leonard P James, Gerson Peltz, Holger Thurm, Jill Clancy, Jennifer Hibma. Clin Pharmacol Ther 2021
Times Cited: 6







List of co-cited articles
11 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


Lorlatinib in non-small-cell lung cancer with ALK or ROS1 rearrangement: an international, multicentre, open-label, single-arm first-in-man phase 1 trial.
Alice T Shaw, Enriqueta Felip, Todd M Bauer, Benjamin Besse, Alejandro Navarro, Sophie Postel-Vinay, Justin F Gainor, Melissa Johnson, Jorg Dietrich, Leonard P James,[...]. Lancet Oncol 2017
363
66


Lorlatinib in patients with ALK-positive non-small-cell lung cancer: results from a global phase 2 study.
Benjamin J Solomon, Benjamin Besse, Todd M Bauer, Enriqueta Felip, Ross A Soo, D Ross Camidge, Rita Chiari, Alessandra Bearz, Chia-Chi Lin, Shirish M Gadgeel,[...]. Lancet Oncol 2018
357
50

First-Line Lorlatinib or Crizotinib in Advanced ALK-Positive Lung Cancer.
Alice T Shaw, Todd M Bauer, Filippo de Marinis, Enriqueta Felip, Yasushi Goto, Geoffrey Liu, Julien Mazieres, Dong-Wan Kim, Tony Mok, Anna Polli,[...]. N Engl J Med 2020
209
33

Alectinib versus Crizotinib in Untreated ALK-Positive Non-Small-Cell Lung Cancer.
Solange Peters, D Ross Camidge, Alice T Shaw, Shirish Gadgeel, Jin S Ahn, Dong-Wan Kim, Sai-Hong I Ou, Maurice Pérol, Rafal Dziadziuszko, Rafael Rosell,[...]. N Engl J Med 2017
33

Brigatinib versus Crizotinib in ALK-Positive Non-Small-Cell Lung Cancer.
D Ross Camidge, Hye Ryun Kim, Myung-Ju Ahn, James Chih-Hsin Yang, Ji-Youn Han, Jong-Seok Lee, Maximilian J Hochmair, Jacky Yu-Chung Li, Gee-Chen Chang, Ki Hyeong Lee,[...]. N Engl J Med 2018
421
33

Clinical Management of Adverse Events Associated with Lorlatinib.
Todd M Bauer, Enriqueta Felip, Benjamin J Solomon, Holger Thurm, Gerson Peltz, Marc D Chioda, Alice T Shaw. Oncologist 2019
44
33

Ensartinib vs Crizotinib for Patients With Anaplastic Lymphoma Kinase-Positive Non-Small Cell Lung Cancer: A Randomized Clinical Trial.
Leora Horn, Ziping Wang, Gang Wu, Elena Poddubskaya, Tony Mok, Martin Reck, Heather Wakelee, Alberto A Chiappori, Dae Ho Lee, Valeriy Breder,[...]. JAMA Oncol 2021
25
33


Brigatinib Versus Crizotinib in Advanced ALK Inhibitor-Naive ALK-Positive Non-Small Cell Lung Cancer: Second Interim Analysis of the Phase III ALTA-1L Trial.
D Ross Camidge, Hye Ryun Kim, Myung-Ju Ahn, James C H Yang, Ji-Youn Han, Maximilian J Hochmair, Ki Hyeong Lee, Angelo Delmonte, Maria Rosario García Campelo, Dong-Wan Kim,[...]. J Clin Oncol 2020
115
33



Optimized Alectinib Dose Regimen for Treatment of Patients With ALK-Positive Non-Small Cell Lung Cancer Based on Robust Pharmacometric Analyses and Clinical Evidence.
Nicolas Frey, Walter Bordogna, Bogdana Balas, Thorsten Ruf, Venice Archer, Elena Guerini. Clin Pharmacol Ther 2021
2
50

The Evidence REVEAL Study: Exploring the Use of Real-World Evidence and Complex Clinical Trial Design by the European Pharmaceutical Industry.
Peter Varnai, Anoushka Davé, Kristine Farla, Anke Nooijen, Liana Petrosova. Clin Pharmacol Ther 2021
5
20

Application of quantitative systems pharmacology to guide the optimal dosing of COVID-19 vaccines.
Mario Giorgi, Rajat Desikan, Piet H van der Graaf, Andrzej M Kierzek. CPT Pharmacometrics Syst Pharmacol 2021
6
16

Response to "Optimized Alectinib Dose Regimen for Treatment of Patients With ALK-Positive NSCLC Based on Robust Pharmacometric Analyses and Clinical Evidence".
Stefanie L Groenland, Dieuwertje R Geel, Jos H Beijnen, Egbert F Smit, Alwin D R Huitema, Neeltje Steeghs. Clin Pharmacol Ther 2021
1
100


Use of Partial Area Under the Curve in Bioavailability or Bioequivalence Assessments: A Regulatory Perspective.
Lanyan Fang, Ramana Uppoor, Mingjiang Xu, Satish Sharan, Hao Zhu, Nilufer Tampal, Bing Li, Lei Zhang, Robert Lionberger, Liang Zhao. Clin Pharmacol Ther 2021
1
100

Current and Next Steps Toward Prediction of Human Dose for Gene Therapy Using Translational Dose-Response Studies.
Sergey Aksenov, John C Roberts, Ganesh Mugundu, Karen Thudium Mueller, Indranil Bhattacharya, Michael A Tortorici. Clin Pharmacol Ther 2021
4
25

Model Informed Drug Development: Collaboration Through A Common Framework.
Richard J Anziano, Peter A Milligan. Clin Pharmacol Ther 2021
2
50

Industrial Perspective on the Benefits Realized From the FDA's Model-Informed Drug Development Paired Meeting Pilot Program.
Gerald R Galluppi, Satjit Brar, Luzelena Caro, Yuan Chen, Nicolas Frey, Hans Peter Grimm, Deanne Jackson Rudd, Chi-Chung Li, Mindy Magee, Arnab Mukherjee,[...]. Clin Pharmacol Ther 2021
4
25

A Model-Based Workflow to Benchmark the Clinical Cholestasis Risk of Drugs.
Vanessa Baier, Olivia Clayton, Ramona Nudischer, Henrik Cordes, Annika R P Schneider, Christoph Thiel, Timo Wittenberger, Wolfgang Moritz, Lars M Blank, Ulf P Neumann,[...]. Clin Pharmacol Ther 2021
1
100

A Model-Based Approach to Assess Unstable Creatinine Clearance in Critically Ill Patients.
Sami Ullah, Michael Zoller, Ulrich Jaehde, Mikayil Huseyn-Zada, Thomas Weig, Uwe Fuhr, Usman Arshad, Johannes Zander, Max Taubert. Clin Pharmacol Ther 2021
1
100

Physiologically Based Pharmacokinetic Model Qualification and Reporting Procedures for Regulatory Submissions: A Consortium Perspective.
Mohamad Shebley, Punam Sandhu, Arian Emami Riedmaier, Masoud Jamei, Rangaraj Narayanan, Aarti Patel, Sheila Annie Peters, Venkatesh Pilla Reddy, Ming Zheng, Loeckie de Zwart,[...]. Clin Pharmacol Ther 2018
152
16


The Complex Roadmap to Infectious Disease Innovation: The Intersection of Bugs, Drugs, and Special Populations.
Melanie R Nicol, Emily J Cicali, Shirley K Seo, Gauri G Rao. Clin Pharmacol Ther 2021
2
50

Physiologically-Based Pharmacokinetic Models for Evaluating Membrane Transporter Mediated Drug-Drug Interactions: Current Capabilities, Case Studies, Future Opportunities, and Recommendations.
Kunal S Taskar, Venkatesh Pilla Reddy, Howard Burt, Maria M Posada, Manthena Varma, Ming Zheng, Mohammed Ullah, Arian Emami Riedmaier, Ken-Ichi Umehara, Jan Snoeys,[...]. Clin Pharmacol Ther 2020
51
16

Drug-Drug Interactions Involving Renal OCT2/MATE Transporters: Clinical Risk Assessment May Require Endogenous Biomarker-Informed Approach.
Sumathy Mathialagan, Bo Feng, A David Rodrigues, Manthena V S Varma. Clin Pharmacol Ther 2021
6
16

Public Workshop Summary Report on Fiscal Year 2021 Generic Drug Regulatory Science Initiatives: Data Analysis and Model-Based Bioequivalence.
Jieon Lee, Yuqing Gong, Sid Bhoopathy, Charles E DiLiberti, Andrew C Hooker, Amin Rostami-Hodjegan, Stephan Schmidt, Sandra Suarez-Sharp, Viera Lukacova, Lanyan Fang,[...]. Clin Pharmacol Ther 2021
1
100

Precision Dosing: The Clinical Pharmacology of Goldilocks.
Richard W Peck, Mohamed H Shahin, Alexander A Vinks. Clin Pharmacol Ther 2021
5
20

Good Practices in Model-Informed Drug Discovery and Development: Practice, Application, and Documentation.
S F Marshall, R Burghaus, V Cosson, S Y A Cheung, M Chenel, O DellaPasqua, N Frey, B Hamrén, L Harnisch, F Ivanow,[...]. CPT Pharmacometrics Syst Pharmacol 2016
170
16


A Drug-Drug Interaction Study Evaluating the Effect of Givosiran, a Small Interfering Ribonucleic Acid, on Cytochrome P450 Activity in the Liver.
Daphne Vassiliou, Eliane Sardh, Pauline Harper, Amy R Simon, Valerie A Clausen, Nader Najafian, Gabriel J Robbie, Sagar Agarwal. Clin Pharmacol Ther 2021
6
16

Exposure-Response Analyses for Therapeutic Dose Selection of Belantamab Mafodotin in Patients With Relapsed/Refractory Multiple Myeloma.
Geraldine Ferron-Brady, Chetan Rathi, Jon Collins, Herbert Struemper, Joanna Opalinska, Sandra Visser, Roxanne C Jewell. Clin Pharmacol Ther 2021
1
100

Quantitative Clinical Pharmacology Supports the Bridging From i.v. Dosing and Approval of s.c. Rituximab in B-Cell Hematological Malignancies.
Candice Jamois, Ekaterina Gibiansky, Leonid Gibiansky, Clarisse Chavanne, Peter N Morcos, Christine McIntyre, Martin Barrett, Linda Lundberg, Artem Zharkov, Axel Boehnke,[...]. Clin Pharmacol Ther 2021
1
100



Extended Survival and Prognostic Factors for Patients With ALK-Rearranged Non-Small-Cell Lung Cancer and Brain Metastasis.
Kimberly L Johung, Norman Yeh, Neil B Desai, Terence M Williams, Tim Lautenschlaeger, Nils D Arvold, Matthew S Ning, Albert Attia, Christine M Lovly, Sarah Goldberg,[...]. J Clin Oncol 2016
229
16

The Effect of Rifampin on the Pharmacokinetics and Safety of Lorlatinib: Results of a Phase One, Open-Label, Crossover Study in Healthy Participants.
Joseph Chen, Huiping Xu, Sylvester Pawlak, Leonard P James, Gerson Peltz, Kimberly Lee, Katherine Ginman, Michelle Bergeron, Yazdi K Pithavala. Adv Ther 2020
14
16


PF-06463922, an ALK/ROS1 Inhibitor, Overcomes Resistance to First and Second Generation ALK Inhibitors in Preclinical Models.
Helen Y Zou, Luc Friboulet, David P Kodack, Lars D Engstrom, Qiuhua Li, Melissa West, Ruth W Tang, Hui Wang, Konstantinos Tsaparikos, Jinwei Wang,[...]. Cancer Cell 2015
274
16

First-line crizotinib versus chemotherapy in ALK-positive lung cancer.
Benjamin J Solomon, Tony Mok, Dong-Wan Kim, Yi-Long Wu, Kazuhiko Nakagawa, Tarek Mekhail, Enriqueta Felip, Federico Cappuzzo, Jolanda Paolini, Tiziana Usari,[...]. N Engl J Med 2014
16

Targeting brain metastases in ALK-rearranged non-small-cell lung cancer.
Isabella Zhang, Nicholas G Zaorsky, Joshua D Palmer, Ranee Mehra, Bo Lu. Lancet Oncol 2015
112
16

Consensus Recommendations for Management and Counseling of Adverse Events Associated With Lorlatinib: A Guide for Healthcare Practitioners.
Mollie Reed, Aimee-Lauren S Rosales, Marc D Chioda, Lindsey Parker, Geeta Devgan, Jacob Kettle. Adv Ther 2020
10
16

A user's guide to lorlatinib.
Misako Nagasaka, Yubin Ge, Ammar Sukari, Geetika Kukreja, Sai-Hong Ignatius Ou. Crit Rev Oncol Hematol 2020
11
16

Mechanisms of acquired crizotinib resistance in ALK-rearranged lung Cancers.
Ryohei Katayama, Alice T Shaw, Tahsin M Khan, Mari Mino-Kenudson, Benjamin J Solomon, Balazs Halmos, Nicholas A Jessop, John C Wain, Alan Tien Yeo, Cyril Benes,[...]. Sci Transl Med 2012
920
16

Molecular Mechanisms of Resistance to First- and Second-Generation ALK Inhibitors in ALK-Rearranged Lung Cancer.
Justin F Gainor, Leila Dardaei, Satoshi Yoda, Luc Friboulet, Ignaty Leshchiner, Ryohei Katayama, Ibiayi Dagogo-Jack, Shirish Gadgeel, Katherine Schultz, Manrose Singh,[...]. Cancer Discov 2016
633
16

Insights into brain metastasis in patients with ALK+ lung cancer: is the brain truly a sanctuary?
Gouji Toyokawa, Takashi Seto, Mitsuhiro Takenoyama, Yukito Ichinose. Cancer Metastasis Rev 2015
61
16

Updated Efficacy and Safety Data and Impact of the EML4-ALK Fusion Variant on the Efficacy of Alectinib in Untreated ALK-Positive Advanced Non-Small Cell Lung Cancer in the Global Phase III ALEX Study.
D Ross Camidge, Rafal Dziadziuszko, Solange Peters, Tony Mok, Johannes Noe, Malgorzata Nowicka, Shirish M Gadgeel, Parneet Cheema, Nick Pavlakis, Filippo de Marinis,[...]. J Thorac Oncol 2019
187
16



Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.